STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more

The FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.

Read it at STAT News ↗

← Front page